Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

NCT05595889 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Small Cell Lung Cancer
Angiogenesis
Chemotherapy Effect

Interventions

DRUG: Surufatinib
DRUG: Irinotecan

Sponsor

Fujian Cancer Hospital